Status:
COMPLETED
Safety and Efficacy Study of AC-3933 in Adults With Mild to Moderate Alzheimer's Disease
Lead Sponsor:
Sumitomo Pharma America, Inc.
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
55+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to investigate efficacy and safety of different doses of AC-3933 in patients with mild to moderate Alzheimer's Disease.
Eligibility Criteria
Inclusion
- Mild to moderate Alzheimer's Disease
- Male or female 55 years or older
- Living with caregiver
- Read, understand and speak English
Exclusion
- Need to drive during the study
- Treatment with acetylcholinesterase inhibitors or NMDA antagonist, such as Aricept or Namenda, within 2 weeks of check-up and during the study
- Frequent Smoker
- Frequent Consumer of Caffeine
Key Trial Info
Start Date :
February 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2008
Estimated Enrollment :
171 Patients enrolled
Trial Details
Trial ID
NCT00359944
Start Date
February 1 2006
End Date
September 1 2008
Last Update
July 2 2013
Active Locations (34)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Trials Inc.
LIttle Rock, Alaska, United States, 72205
2
PsyPharma Clinical Research Inc.
Phoenix, Arizona, United States, 85013
3
ClinicalStudies Center LLC
Little Rock, Arkansas, United States, 72205
4
Vertex Clinical Research
Bakersfield, California, United States, 93311